金迪克(688670) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥35,611,056.15, a decrease of 67.81% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was a loss of ¥12,594,311.40, with a year-to-date loss of ¥53,461,400.63[3]. - The basic and diluted earnings per share for Q3 2024 were both -¥0.10[3]. - Total operating revenue for the first nine months of 2024 was CNY 38,899,225.52, a decrease of 67.8% compared to CNY 120,843,721.03 in the same period of 2023[15]. - Net profit for the first nine months of 2024 was a loss of CNY 53,461,400.63, compared to a loss of CNY 11,077,111.92 in the same period of 2023[17]. - Basic and diluted earnings per share for the first nine months of 2024 were both CNY -0.43, compared to CNY -0.09 in the same period of 2023[17]. Research and Development - Research and development expenses totaled ¥7,062,085.62 for Q3 2024, representing 19.83% of revenue, a significant increase of 50.64 percentage points year-over-year[4]. - Research and development expenses for the first nine months of 2024 were CNY 15,684,998.97, an increase from CNY 12,049,272.55 in the same period of 2023[16]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥1,558,172,277.20, a decrease of 4.50% from the end of the previous year[4]. - The total equity attributable to shareholders at the end of Q3 2024 was ¥1,317,620,227.81, down 3.90% from the previous year[4]. - Total liabilities as of the end of the reporting period were CNY 240,552,049.39, down from CNY 260,519,676.81 at the end of the previous year[15]. - The total current assets amounted to ¥628,818,075.32, a decrease from ¥722,242,458.52 as of December 31, 2023, representing a decline of approximately 12.93%[13]. - The total assets of the company were CNY 1,558,172,277.20, a decrease from CNY 1,631,601,305.25 at the end of the previous year[15]. Cash Flow - The company reported a net cash flow from operating activities of -¥127,334,109.03 year-to-date, a decrease of 306.17% compared to the previous year[3]. - In the first three quarters of 2024, the net cash flow from operating activities was -127,334,109.03 RMB, a significant decline compared to 61,761,430.14 RMB in the same period of 2023[18]. - Total cash inflow from operating activities was 50,815,849.54 RMB, down from 329,424,695.98 RMB year-over-year[18]. - The net increase in cash and cash equivalents was -36,038,778.50 RMB, contrasting with an increase of 255,840,622.91 RMB in the previous year[19]. - The ending balance of cash and cash equivalents was 34,404,810.28 RMB, down from 430,569,549.73 RMB year-over-year[19]. Sales and Market Conditions - The company experienced a significant decline in sales due to the temporary shutdown of its flu vaccine workshop in Q3 2023, resulting in no sales revenue for that period[4]. - The company attributed the decline in revenue to a decrease in flu vaccine sales and a price reduction for the 2024/2025 flu season products[8]. - The company reported a total revenue of 37,811,047.56 RMB from sales and services in the first three quarters of 2024, compared to 318,684,352.44 RMB in the same period of 2023[18]. Government Support - The company received government subsidies amounting to ¥58,150.02 during the reporting period, which were closely related to its normal business operations[5].